GSK plc Form 6-K Summary
Business context and reporting period
GSK plc, a global biopharmaceutical company, filed this Form 6-K for September 2026. The filing reports an insider transaction notification rather than periodic financial results.
Transaction and key metrics
- Person: Maya Martinez-Davis, President, US, and a person discharging managerial responsibilities.
- Instrument: GSK American Depositary Shares (ADS), ISIN US37733W2044.
- Transaction: Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account.
- Date: September 22, 2026.
- Price and volume: $50.7200 per ADS; 9.414 ADS.
- Reported venue: New York Stock Exchange.
- Implied transaction value: Approximately $477.48, based on the disclosed price and volume.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial-period metrics.
Material changes versus the prior comparable period
No comparable-period financial information or material operating changes are reported.
Guidance, outlook, risks, contingencies, and unusual items
No guidance, outlook, risk factors, contingencies, or unusual operating items are disclosed. The reported activity is a routine notional acquisition under an executive savings plan and is not described as an open-market purchase by the executive.
Investor verification points
- Verify the ADS price, fractional volume, transaction date, and plan-related nature of the acquisition.
- Confirm that the filing is an insider transaction notification and not an earnings or financial-results filing.
- Review subsequent GSK filings for additional transactions, financial results, guidance, or material developments.